cells. These studies also confirm the feasibility of employing negative hematopoietic regulators to augment the sequestration of normal HPC among the cytoIt is believed that long-term cultures of CML marrow cells favor the outgrowth of BCR/ABL negative hematokine nonresponsive fraction of CD34
MIP-1␣ cells in primary short-term cultures, maintained in the presence or absence of macrophage inhibitory protein-1 alpha (MIP-1␣), was tracked with the membrane dye
Chronic myeloid leukemia (CML) is a hematopoietic stem PKH2. After 7 to 10 days it was possible to distinguish cell disease characterized by the presence of the distinctive between cytokine responsive (CR) CD34
؉ cells (cells Ph chromosome in the leukemic cells of more than 90% of which had divided thus becoming PKH2 dim ) and cytoall patients. 1 The translocation creating the Ph chromosome kine nonresponsive (CNR) CD34
؉ cells (cells which had encodes a fusion protein, p210 bcr/abl, with increased tyronot divided and had therefore remained PKH2 bright ). CR sine kinase activity. 2, 3 This increased activity results in an and CNR CD34 ؉ cells were isolated by flow cytometric increased proliferative advantage for CML cells.
4,5
cell sorting, seeded in secondary long-term cultures, and Although allogeneic bone marrow transplantation (BMT) is their progeny cells assayed weekly for their clonogenic a relatively successful therapy for CML, many patients may progenitor cell content and expression of BCR/ABL by not be eligible for BMT because of advanced age or lack reverse transcriptase polymerase chain reaction (RTof a suitable matched donor. This led to the adoption of PCR). Whereas CNR cells isolated from control priautologous transplantation for CML 6 especially in light of mary cultures (control/CNR) sustained in vitro hematoaccumulating evidence suggesting the presence of normal poiesis, similar cells from cultures treated with MIP-1␣ primitive hematopoietic progenitor cells (HPC) within (MIP-1␣/CNR) supported a higher and, in some CML marrow. [7] [8] [9] [10] [11] The first documentation of the existence patients, a more extended production of clonogenic of normal primitive HPC in CML marrow was presented HPC, indicating that MIP-1␣ was able to maintain by Coulombel et al 12 who then went on to demonstrate that primitive HPC in a quiescent state. Predominance of although these cells remain dormant in vivo, they can be BCR/ABL negative progenitors in vitro was more eviactivated, and therefore detected and selected, in vitro. [13] [14] [15] dent in secondary cultures initiated with CNR cells than Autologous BMT offers a potential curative strategy, if norin those initiated with CR cells, especially those estabmal lymphohematopoietic stem cells in CML marrow or lished with MIP-1␣/CNR cells. Of interest is the peripheral blood could be separated from neoplastic cells observed decline in the percentage of BCR/ABL+ proso as to allow restoration of normal hematopoiesis in genitors in these cultures with time. Whereas up to myeloablated patients. Separation of normal hematopoietic 100% of progenitors were BCR/ABL؉ on day 0, by day progenitor cells from their leukemic counterparts has been 14, only 46% of progenitors in MIP-1␣/CNR secondary achieved through the maintenance of CML marrow cells in cultures were BCR/ABL؉ and by day 28 and beyond, long-term bone marrow cultures (LTBMC), a process the percentage of BCR/ABL؉ progenitors dropped to which depletes Ph positive cells, 9, 16 or through the isolation below 20%. These results suggest that the quiescent natof a phenotypically defined group of marrow cells (CD34 
Materials and methods

Short-term cultures of total CD34 + cells Patients
On day 0, cells stained with PKH2 were split into two frac-A total of eight chronic myeloid leukemia patients were tions and seeded at 2 × 10 5 cells/well into 48-well tissue studied. The clinical characteristics of these patients are culture plates in 1 ml of complete medium with or without presented in Table 1 . All patients had peripheral blood and 10 ng/ml of murine MIP-1␣. Murine MIP-1␣ was obtained bone marrow profiles consistent with CML and displayed from R&D Systems, (Minneapolis, MN, USA) and was prePh chromosome, t(9;22)(q34;q11). Patients 1 to 7 received pared and stored according to manufacturer's instructions. hydroxyurea (HU) while the last patient received interferon Complete medium consisted of IMDM supplemented with (IFN) therapy at the time of collection of BM samples.
10% FBS, l-glutamine and antibiotics (penicillin, 100 U/ml and streptomycin, 100 g/ml). All of the complete medium ingredients (except for FCS) were obtained from BioWhitBone marrow collection and fractionation taker (Walkersville, MD, USA) while FCS was obtained from Hyclone (Logan, UT, USA). Murine MIP-1␣ (10 Bone marrow aspirates were collected from the posterior iliac crest after informed consent was obtained. These studng/ml) was added again to the culture on day 3. At initiation, and every 48 h thereafter, cultures were supies were approved by the Indiana University Institutional Review Board. Marrow samples were immediately diluted plemented with 200 ng/ml stem cell factor (SCF), 100 ng/ml of interleukin-3 (IL-3) and 50 ng/ml of recombinant 1:1 with Iscove's modified Dulbecco's media (IMDM) supplemented with 20 U/ml sodium heparin. Low-density bone granulocyte-macrophage colony-stimulating factor (GM-CSF). Cultures receiving MIP-1␣ will be referred to as marrow (LDBM) cells were obtained by Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA) density centrifugation.
'MIP-1␣ cultures' while those sustained with SCF, IL-3 and GM-CSF only will be referred to as 'control cultures'. Cells were fractionated by immunomagnetic selection to obtain CD34 + cells, as previously described. 23 Care was taken to avoid cell densities exceeding 1 × 10 6 /ml.
Whenever such densities were reached, cultures were split These cultures were initiated with an average of 2.4 × 10 4 cells (for CNR fractions) and 4.5 × 10 4 cells (for CR and fresh medium and cytokines were added. After 7 to 10 days in culture, cells were stained with PE-conjugated fractions). Secondary cultures were not treated with MIP-1␣, but were supplemented at initiation, and every 48 h CD34 for 20 min on ice. Cells stained with PKH2 on day 0, then fixed, were used to determine the green fluorescence thereafter, with the three cytokines mentioned above. At weekly intervals, cultures were demi-depopulated and the intensity corresponding to cells that had not divided. This allowed for the localization, within a dual parameter historemaining cells were resupplied with fresh medium and cytokines. The cells were collected and used in hematogram, of the group of CD34 + cells that have remained quiescent and are therefore CD34 + PKH2 bright ( Figure 1 ). poietic progenitor cell assays as described below. These cells were identified as cytokine nonresponsive cells (CNR). As previously described, 21, 22 the size of the CNR Hematopoietic progenitor assay fraction was in general less than 5% of total cells analyzed. After determining the relative size of this group of cells, a
Freshly isolated CD34 + cells (10 3 ) or different numbers of cultured cells (between 2 × 10 3 to 75 × 10 3 ) were suspended group of approximately equal size of CD34
+ cells displaying the most dim PKH2 fluorescence was isolated as in 35-mm tissue culture dishes in 1 ml containing 30% FCS, 5 × 10 −5 m/l 2-mercaptoethanol, 100 ng/ml SCF, 10 CD34
+ PKH2 dim ( Figure 1 ). Since these cells had proliferated in response to cytokine stimulation, they were labeled ng/ml IL-3, 10 ng/ml IL-6, 5 ng/ml GM-CSF, 2 U/ml erythropoietin and 1.1% methylcellulose in IMDM. All as cytokine responsive (CR) cells. As such, four groups of cells were obtained; two from the control group, control/CR measurements were performed in duplicate. In assays of freshly isolated CD34 + cells only, one set of duplicate culand control/CNR and two from the MIP-1␣ group, MIP-1␣/CR and MIP-1␣/CNR. The purity of all four fractions ture dishes received 10 ng/ml MIP-1␣ which was added to the semi-solid medium components listed above. MIP-1␣ exceeded 90% as determined by re-examination of the fluorescence distribution of sorted cells relative to the sort was not added to progenitor cell assays initiated with cells harvested from long-term secondary cultures. Cultures were windows used to initially identify and isolate these fractions.
incubated at 37°C in 100% humidified 5% CO 2 in air. After 14 days, BFU-E, CFU-GM and CFU-GEMM were enumerated using an inverted microscope. Colonies were individuLong-term cell culture ally plucked and analyzed by RT-PCR for the presence of the BCR/ABL transcript. As many colonies as possible, up Secondary, non-stromal cell-based, long-term cultures of both CNR and CR cells isolated from primary cultures on to 15 per culture dish, were plucked and analyzed. days 7-10 were established in 1 ml of complete medium in flat-bottomed 48-well plates, as previously described.
24,25
Reverse transcription and PCR analysis
Total RNA was isolated from individual hematopoietic colonies in a single-step liquid-phase separation 26 using tripure isolation reagent (Boehringer Mannheim, Indianapolis, IN, USA) as per the manufacturer's instructions. One microgram of RNA was reverse transcribed in the presence of 1 g of reverse transcriptase primer (abl-RT) (5′AACGAAAAGGTTGGGGTC3′) and Moloney murine leukemia virus (M-MLV) reverse transcriptase according to the manufacturer's protocol (GIBCO-BRL, Gaithersburg, MD, USA). The first strand cDNA thus generated was split into two parts and amplified for BCR/ABL and normal The rationale for using MIP-1␣ in these experiments was were denaturation for 1 min at 94°C, annealing at 65°C for that this chemokine may preferentially suppress normal 1 min and extension at 72°C for 1 min for a total of 30 primitive HPC, and possibly stem cell activation and procycles. Reactions were performed in a Perkin Elmer Cetus liferation. Consequently, it may retain a higher number of DNA thermal cycler. One to two microliters of the product primitive HPC among CNR cells than is possible when of the first round PCR was once again subjected to another CD34 + cells are stimulated with growth promoting cyto-30 cycles of PCR with identical amplification conditions kines only. We also hypothesized that compared to using the nested primer pairs. The sequence of upstream control/CNR cells, cytokine nonresponsive cells isolated nested primer for BCR/ABL was 5′GTTCCTGATCTC-from primary CML CD34 + cells cultured with MIP-1␣ CTCTGACTATGAGCGTGCA3′ and 5′CTCAGACCC-would contain a higher frequency of BCR/ABL negative TGAGGCTCAAAGTCAGATGCT3′ the sequence of colony forming units. To that effect, CNR and CR fractions downstream nested primer. The upstream nested primer for were isolated from primary cultures of CD34 + cells initiated normal ABL located in exon 1a and exon 1b were 5′ 7 to 10 days earlier with or without MIP-1␣ and all four GCCCGATCGTTCGCTTGGCGCAAAATGTTGG3′ and groups of cells were assessed for their BCR/ABL+ progeni-5′ GCCTGCCCTGCATTTTATCAAAGGAGCAGGG 3′
tor cell content and were also used to establish secondary respectively and of downstream primer, 5′-CTCAlong-term cultures. The percentage of cultured cells GACCCTGAGGCTCAAAGTCAGATGCT-3′.
RNA retained as CNR cells was always less than 5% of all cells obtained from K562, an erythroleukemia cell line, was analyzed on day 7 to 10, and did not differ significantly included as a positive control and a PCR reagent control in size between control and MIP-1␣ cultures (Figure 1 ). was used as a negative control with each PCR analysis.
Immediately after their selection, these groups of cells contained from as low as 47% (in the MIP-1␣/CNR fraction) to as high as 72% (in the MIP-1␣/CR fraction) BCR/ABL+ Statistical analysis progenitors with the control counterparts of these two fractions containing 65% and 58% BCR/ABL+ progenitors, Where applicable, data are reported as mean Ϯ s.e. Statistirespectively (n = 7 to 10 for every fraction). cal comparison between paired data from different groups Total cellular production in secondary cultures initiated was performed using a two-tailed t-test.
with MIP1-␣/CNR cells exceeded that observed in parallel cultures of control/CNR cells (data not shown). This trend of greater production of cells in MIP-1␣/CNR secondary cultures than in control/CNR cultures was evident in three Results out of the six sets of cultures examined while in two other sets similar numbers of cells were produced in both types Effect of MIP-1␣ on primary short-term suspension of culture. As can be seen in Figure 2 , the majority of cultures Duplicate short-term suspension cultures were initiated with total CD34 + cells from six patients. One replicate culture received SCF, IL-3, and GM-CSF only (control cultures) while to the other, MIP-1␣ was also added (MIP-1␣ cultures). Following 7 to 10 days in culture, cells were harvested and counted. Comparison of fold-expansion achieved in both types of cultures demonstrated that, in general, control cultures produced a slightly higher cell number than MIP-1␣ cultures: 10-fold vs 8.1-fold expansion, respectively. However, these differences did not achieve statistical significance (P Ͻ 0.1) suggesting that MIP-1␣ exerted minimal effect on the proliferation of total CD34 + cells. 
CD34
+ cells with MIP1-␣ was to assess whether negative isolated from primary cultures of patient 8 in Table 1 lyzed on a per patient basis comparing the retention of BCR/ABL negative progenitors in every fraction. Figure 3 depicts total colony production in all four secondary cultures from one CML patient at 2 and 3 weeks with those secondary cultures initiated with MIP-1␣/CNR cells produced more clonogenic cells than their counterparts testing as BCR/ABL+ shown as a percentage of the total number of clonogenic cells. Not only did the secondary initiated with control/CNR cells. However, when examined collectively, increased cellular production in MIP1-␣/CNR culture initiated with MIP-1␣/CNR cells produce the largest number of progenitor cells, only 10% of assayable procultures did not translate into a statistically significant (P Ͼ 0.1) increase in the production of assayable progenitors genitors generated in this culture on day 21 tested BCR/ABL+ (Figure 3 ). The sensitivity of the RT-PCR compared to control/CNR cultures. Most likely, the lack of any statistically significant difference could be attributed to assay and its ability to detect single BCR/ABL+ progenitors is demonstrated in Figure 4 which depicts results from the the degree of variability demonstrated in the behavior of cultured cells from one patient to the other. Of interest is analysis of seven BCR/ABL+ and two BCR/ABL negative hematopoietic colonies. Colonies failing to amplify normal that over the span of all secondary cultures established with the four groups of sorted cells, total production of clonog-ABL sequences were excluded from any further analysis (lanes 6 and 10 from the left in Figure 4 ). enic cells in the CNR and CR fractions derived from primary cultures treated with MIP1-␣, exceeded that observed
We next analyzed the RT-PCR data collectively. Maintenance of BCR/ABL negative progenitors in the four fracwith similar fractions derived from primary control cultures. Still, this difference in total colony-forming units was tions of all patients examined was assessed over two separate time intervals; namely days 7 to 14 and days 14 to 35 not statistically significant. Production of colony-forming cells in the CR and CNR fractions did not appear to be of culture. The time frame between days 14 and 35 was chosen in order to group together all data points of peak dependent on any clinical characteristic of these patients. production of assayable progenitors detected in all longlyzed for the retention of BCR/ABL+ progenitors between days 14 and 35, less than 50% of assayable progenitors in term cultures analyzed. As can be seen in Figure 5a , by 14 days of culture, more than 50% of progenitors in all fracall fractions, except control/CR, were BCR/ABL+ ( Figure  5b ). In fact only 18.7 Ϯ 4% (range 0 to 40%) of progenitors tions tested were BCR/ABL+ except in the MIP-1␣/CNR fraction. At this early stage of the culture, the difference in maintained in MIP-1␣/CNR cultures were BCR/ABL+ (Figure 5b ). On the other hand, none of the control/CR, the percentage of BCR/ABL+ progenitors between control/CR and control/CNR fractions was not statistically control/CNR, and MIP-1␣/CR cultures contained less than 15% BCR/ABL+ clonogenic progenitors while harboring significant (Figure 5a ) whereas that between MIP-1␣/CR and MIP-1␣/CNR fractions was (P Ͻ 0.05). This is as high as 86% BCR/ABL+ progenitors. At this time point however, differences in the percentage of BCR/ABL+ proespecially interesting when one considers that the fraction of BCR/ABL+ clonogenic cells in control/CR, genitors between control/CR and control/CNR fractions as well as between MIP-1␣/CR and MIP-1␣/CNR fractions control/CNR, and MIP-1␣/CR ranged from as low as 20% to as high as 100%, while that among MIP-1␣/CNR cells ( Figure 5b ) were statistically significant (P Ͻ 0.05). More importantly, the difference in the percentage of BCR/ABL+ did not exceed 71% for all patients examined. When anaprogenitors within control/CNR and MIP-1␣/CNR cells was statistically significant (P Ͻ 0.05) suggesting that the long observed decline in the percentage of BCR/ABL+ progenitors among cultured cells 28 may indeed occur among the more primitive CNR fraction of cultured cells, and that MIP-1␣ may augment the retention of these progenitors within the fraction of cytokine nonresponsive cells.
We also investigated whether a significant difference in the percentage of BCR/ABL negative progenitor cells could be detected at the time of peak production of assayable progenitor cells in each of the four culture conditions examined rather than during the entire period of days 14 to 35. As can be seen in Figure 5c at their respective colony production time points, MIP-1␣/CNR cultures contained a statistically significant lower number of BCR/ABL negative progenitors compared to those from MIP-1␣/CR or control/CNR cultures. Selection of BCR/ABL negative progenitors from within MIP-1␣/CNR cultures was very reproducible (Table 2) . Based on the average number of CD34 + cells available for these experiments on day 0 (1.17 × 10 6 ) and the number of MIP-1␣/CNR cells recovered by cell sorting on day 7 to 10 (2.4 × 10 4 , which could be doubled if no control cultures are established), it appears that only + marrow cells maintained with and without MIP-1␣. Data sets obtained between days 7 to 14 and 14 to 35 are presented in panels a and b, respectively while data collected from each culture on its respective peak production of assayable progenitor cells are shown in panel c. Secondary cultures from all four fractions of cells isolated from primary cultures of all patients studied were maintained as described in Materials and methods. Individual colonies produced in weekly progenitor cell assays were plucked and analyzed by RT-PCR for their BCR/ABL status. Each bar in panels a and b represents the mean percentage of BCR/ABL+ colonies from within all colonies tested from all patients analyzed between days 7 to 14 and days 14 to 35. Bars in panel c represent the mean percentage of BCR/ABL+ colonies from within all colonies tested from all patients analyzed on the day of peak production of assayable progenitor cells. The number of data points analyzed for every bar in panels a and b ranged between 7 and 12 and that for bars in panel c was 6. Each data point was derived from the analysis of between 6 and 15 individual colonies. Only 13 data points out of a total of 75 were generated from the analysis of fewer than six colonies. Statistical differences between groups are as such. 
Enrichment of BCR/ABL negative BM CD34
+ cells P Veena et al 1219 be enriched for BCR/ABL negative primitive HPC. An array of both inhibitory and stimulatory effects on the growth of different classes of progenitor cells have been previously reported for MIP1-␣. It was therefore essential Discussion to assess any positive or negative effect MIP1-␣ may have on the growth of any group of CD34 + cells in our culture Chronic myeloid leukemia, a neoplastic disorder affecting the hematopoietic system at the stem cell level, is believed system at different time points. Neither initial colony formation, nor the kinetics of cell and assayable progenitor to affect a subset of these cells, but not all. Information demonstrating the presence of normal stem cells in the marproduction in short-and long-term hematopoietic cultures were significantly altered by the addition of MIP1-␣. Lack row of many CML patients [10] [11] [12] 15, 29 has become vital for the development of procedures which may allow for their of detectable MIP1-␣ growth inhibitory or stimulatory effects in our studies may be due to the concentration of differential manipulation. Various in vitro methodologies have been devised to purge leukemic marrow in order to MIP1-␣ used and to the frequency of its addition to the culture. Only when used daily over a period of 6 days, or allow for the restoration of normal hematopoiesis following autografting of the modified graft. Of these approaches, ex at 100 ng/ml, was MIP1-␣ effective in suppressing proliferation and entry of cells into the S phase of the cell vivo expansion of CD34 + cells or their subpopulations have been found to be successful in eliminating malignant cycle. 19, 33 However, in our experience, when added on days 0 and 3 at 10 ng/ml to cultures of total CML CD34 + cells, cells. 10, 12, 15, 30 Obviously, the success of such an approach can be further enhanced if either the growth of contaminat-MIP-1␣ was selective in inhibiting the entry of normal primitive HPC into active phases of cell cycle and in retaining leukemic CD34 + cells can be accelerated such that by the end of the culture period, these cells would have ing these cells among the fraction of CNR cells. The presence of BCR/ABL negative primitive HPC among MIPexhausted their hematopoietic potential, most importantly their long-term engraftment capabilities, or if the growth of 1␣/CNR cells was evident from assays performed early after the isolation of PKH2 bright and PKH2 dim CD34 + cells normal CD34 + cells could be slowed down so that only these cells retain the desired functional properties of (Figure 4a ) since PCR analysis at that stage revealed a statistically significant difference in the leukemic progenitor expanded cells.
Since proliferation, differentiation and self-renewal of content of these fractions. With time, maintenance of quiescent normal HPC within isolated MIP-1␣/CNR cells primitive normal hematopoietic cells is the net balance of stimulatory and inhibitory factors, the above-mentioned became more apparent (Figure 4b ). This observation may be best explained by the ability of MIP-1␣ to suppress actitwo alternatives may be applied simultaneously in vitro, if both positive and negative regulators of hematopoiesis were vation, and subsequently, proliferation of normal HPC in response to SCF, IL-3 and GM-CSF stimulation. It is used in short-term expansion cultures. This is especially applicable when one considers the already established eviimportant to point out that, even in the absence of MIP1-␣, the percentage of BCR/ABL+ progenitors among CNR dence demonstrating the preferential growth inhibitory activity of MIP1-␣ on normal primitive HPC but not their cells (control/CNR) declined drastically after 14 days in culture ( Figure 4b ) and was significantly different than that leukemic counterparts. 19, 20 In conclusion, these studies outline a simple approach bility of murine CNR cells to rescue lethally irradiated recipients, thus documenting the maintenance of primitive for the enrichment of BCR/ABL negative progenitors from CML marrow based on the preferential negative regulatory HPC among this fraction of cultured cells. 35 Our present studies appear to indicate that the process of eliminating effects of MIP-1␣ on leukemic, but not normal, primitive HPC. Although as described here, this approach may not BCR/ABL+ progenitors in culture can be further enhanced with MIP-1␣ provided a feasible mechanism allowing for be applicable clinically, minor modifications may render such a procedure feasible for both autologus bone marrow the removal of cytokine activated, highly proliferative cells from culture can be implemented. Although these results transplantation and gene therapy. Under appropriate culture conditions, yet to be established, enrichment of normal validate our initial hypothesis and are rather encouraging, it is prudent to caution that these results were generated primitive HPC according to the procedure outlined in these studies followed by ex vivo expansion could potentially from a limited patient population and that more detailed studies are needed before universal conclusions can be generate a suitable autologous stem cell graft. Similarly, normal primitive HPC isolated by this technique may be drawn. It is also important to note that while procedures described in this paper may potentially reduce relapse from ideal targets for gene therapy in CML. In addition, these studies lend further support to the concept that through an autologus CML bone marrow transplantation, relapse from residual disease will have to be addressed in conjuncproper identification and manipulation of primitive HPC, it may be possible to prepare leukemia-free autografts from tion with such an approach either by inducing a GVL-type response in an autologus setting or via the introduction of CML marrow. drug resistance genes into transplanted HPC.
The question remains however, whether the approach described in these studies for the sequestration of normal Acknowledgements HPC within an identifiable fraction of cultured cells can be translated into a clinical application. At least three major Bedi et al 36 indicated that expression of BCR/ABL mRNA
